Ben Venue Continues Suspension of Manufacturing Activity at Ohio Facility - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Ben Venue Continues Suspension of Manufacturing Activity at Ohio Facility


ePT--the Electronic Newsletter of Pharmaceutical Technology

Ben Venue Laboratories is extending its voluntary suspension of manufacturing at its Bedford, Ohio, facility. The company had originally announced the suspension on Nov. 19, 2011, and announced the extension of the suspension on Dec. 23, 2011.

Ben Venue had suspended manufacturing at the Bedford facility after an internal review indicated that routine preventive maintenance and requalification of some manufacturing equipment was overdue. These issues also were noted in recent inspection findings by FDA, the European Medicines Agency, and other global regulatory agencies. Ben Venue’s operations in Bedford include sterile injectable facilities with aseptic filling, lyophilization, and cytotoxic manufacturing in four factories.

The company says it is looking to restore some manufacturing in the first quarter of 2012. “As we address the facility and equipment issues in each factory, we will resume production, likely one line at a time,” according to a Dec. 23, 2011, company press release. “We are now working to restore some manufacturing in the first quarter of 2012 and will provide updates as they become available.” The company says it continues to conduct a site-wide assessment in order to fully understand the potential impact and implement any appropriate corrective actions that may be needed as quickly as possible.

Ben Venue, however, said that the resumption of certain other manufacturing activities will take longer. “A substantial investment of time and resources will be required to make necessary improvements in the north facility, where several sterile injectable drugs currently in short supply are manufactured,” according to the company statement. “The facility requires major reconstruction that may take up to nine months to complete. We anticipate that no products manufactured in the north facility will be available to patients and healthcare professionals before the fourth quarter of 2012. It should be noted that these expectations are based on our current plans and may be revised in the future.”

See related Pharm Tech articles:

EMA Addresses Ben Venue Quality Issues (ePT, Dec. 15, 2011)

Ben Venue Suspends Manufacturing at Bedford Plant (ePT, Nov. 23, 2011)

Drug Shortages Create Crisis for Manufacturers, Regulators (Pharm. Technol., November 2011)

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
14%
To select process for new products only
23%
To select processes for both new and legacy products
20%
Do not use QbD
25%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
FindPharma Custom Search
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here